Company news
Allarity Therapeutics, Inc. news in 2022
Allarity Therapeutics, Inc.'s news releases, calls and decks from 2022, newest first.
Allarity Therapeutics Reschedules 2022 Annual Stockholders Meeting and Sets New Record Date
November 30, 2022
Allarity Therapeutics Reports Third Quarter 2022 Financial Results
November 14, 2022
Allarity Therapeutics Announces Adjournment of 2022 Annual Meeting of Stockholders
November 6, 2022
Allarity Therapeutics Reports Second Quarter 2022 Financial Results, Provides Recent Operational Highlights, and Regains Compliance with NASDAQ Listing Requirements
October 10, 2022
Allarity Therapeutics Appoints Seasoned Biotechnology Executive Jerry McLaughlin to Board of Directors
September 25, 2022
Allarity Therapeutics to Present at Ladenburg Thalmann Healthcare Conference
September 15, 2022
Allarity Therapeutics Announces Appointment of New Auditor
September 11, 2022
Allarity Therapeutics Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
August 25, 2022
Allarity Therapeutics Refocuses Oncology Pipeline Strategy Towards Combination Therapies
August 1, 2022
Allarity Therapeutics Bolsters Its Board of Directors with Appointment of Prominent Clinical Researcher and Oncology Drug Developer, David A. Roth, M.D.
July 10, 2022
Allarity Therapeutics Announces Executive Leadership Transition
June 28, 2022
Allarity Therapeutics Strengthens Scientific Advisory Board with Appointment of Distinguished Oncologist Roberto Pili, M.D.
June 14, 2022
Allarity Therapeutics Reports First Quarter 2022 Financial Results
May 26, 2022
Correction Notice to Press Release Announcing Financial Results For the Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
May 17, 2022
Allarity Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
May 15, 2022
Allarity Therapeutics Provides Update on Dovitinib Program
March 14, 2022
Allarity Therapeutics Receives Refusal to File Letters from U.S. FDA
February 17, 2022
Allarity Therapeutics and Oncoheroes Biosciences Sign Agreements to Advance Pediatric Cancer Development of Dovitinib and Stenoparib
January 2, 2022
Decks in 2022
- Ladenburg Healthcare Conference September 2022
Conference · 23 slides · Sep 26, 2022
- Investor Presentation (August 2022)
Investor deck · 39 slides · Aug 29, 2022
- Investor Presentation (May 2022)
Investor deck · 38 slides · May 27, 2022
- Investor Presentation (January 2022)
Investor deck · 40 slides · Jan 18, 2022